Pertussis: What the pediatric infectious disease specialist should know

Pediatric Infectious Disease Journal

Volumn 31, Issue 1, 2012, Pages 78-79

  Heininger, Ulrich ^a  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

Author keywords

Bordetella; epidemiology; pertussis

Indexed keywords

AZITHROMYCIN; CLARITHROMYCIN; PERTUSSIS VACCINE;

ADL DISABILITY; ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC THERAPY; APNEA; ARTICLE; BACTERIUM CULTURE; BORDETELLA PARAPERTUSSIS INFECTION; BRAIN DISEASE; BRONCHOPNEUMONIA; DISEASE TRANSMISSION; DRUG EFFICACY; ENZYME LINKED IMMUNOSORBENT ASSAY; EXTRACORPOREAL OXYGENATION; FEVER; HUMAN; IMMUNITY; IMMUNOGENICITY; LUNG INSUFFICIENCY; PERTUSSIS; POLYMERASE CHAIN REACTION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RESPIRATORY DISTRESS SYNDROME; RHINITIS; SEIZURE; SEROLOGY; SINGLE DRUG DOSE; SLEEP DISORDER; THROAT CULTURE; VOMITING;

ADULT; ANTI-BACTERIAL AGENTS; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; COMMUNICABLE DISEASES; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; INFANT; POLYMERASE CHAIN REACTION; SPECIALIZATION; WHOOPING COUGH;

EID: 84855470072     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e31823b034e     Document Type: Article

References (22)

1. Heininger U. Update on pertussis in children. Expert Rev Anti Infect Ther. 2010;8:163-173.
2. Long S, et al. Serologic evidence of subclinical pertussis in immunized children. Pediatr Infect Dis J. 1990;9:700-705. (Pubitemid 20335439)
3. Crameri S, Heininger U. Successful control of a pertussis outbreak in a university children's hospital. Int J Infect Dis. 2008;12:e85-e87.
4. Cherry JD, et al. Defining pertussis epidemiology: clinical, microbiologic and serologic perspectives. Pediatr Infect Dis J. 2005;24(suppl 5):S25-S34. (Pubitemid 40676533)
5. Mortimer EA. Pertussis and its prevention: a family affair. J Infect Dis. 1990;161:473-479.
6. de Greeff SC, et al. Pertussis disease burden in the household: how to protect young infants. Clin Infect Dis. 2010;50:1339-1345.
7. Heininger U, et al. Clinical findings in Bordetella pertussis infections: results of a prospective multicenter surveillance study. Pediatrics. 1997;100: E10.Availableat:www.pediatrics.org/cgi/content/full/100/6/e10.
8. Halasa NB, et al. Fatal pulmonary hypertension associated with pertussis in infants: does extracorporeal membrane oxygenation have a role? Pediatrics. 2003;112:1274-1278. (Pubitemid 37523406)
9. Crowcroft NS, et al. Deaths from pertussis are underestimated in England. Arch Dis Child. 2002;86:336-338. (Pubitemid 34478227)
10. Schläpfer G, et al. Polymerase chain reaction identification of Bordetella pertussis infections in vaccinees and family members in a pertussis vaccine efficacy trial in Germany. Pediatr Infect Dis J. 1995;14:209-214.
11. Templeton KE, et al. Evaluation of real-time PCR for detection of and discrimination between Bordetella pertussis, Bordetella parapertussis, and Bordetella holmesii for clinical diagnosis. J Clin Microbiol. 2003;41:4121-4126. (Pubitemid 37099674)
12. Mertens PL, et al. Sensitivity and specificity of single IgA and IgG antibody concentrations for early diagnosis of pertussis in adults: an evaluation for outbreak management in public health practice. BMC Infect Dis. 2007;7:53.
13. Bergquist S, et al. Erythromycin in the treatment of pertussis: a study of bacteriologic and clinical effects. Pediatr Infect Dis J. 1987;6:458-461. (Pubitemid 17072089)
14. Centers for Disease Control Prevention. Recommended antimicrobial agents for the treatment and postexposure prophylaxes of pertussis: 2005 CDC guidelines. Morb Mortal Wkly Rep. 2005; 54(RR-14):1-16.
15. Halperin SA, et al. A randomized, placebo-controlled trial of erythromycin estolate chemoprophylaxis for household contacts of children with culture-positive Bordetella pertussis infection. Pediatrics. 1999;104:e42. Available at: http://www.pediatrics.org/cgi/content/full/104/4/e42.
16. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J. 1997;16:S90-S96. (Pubitemid 27175031)
17. Heininger U, et al. Evidence of efficacy of the Lederle/Takeda acellular pertussis component diphtheria and tetanus toxoids and pertussis vaccine but not the Lederle whole-cell component diphtheria and tetanus toxoids and pertussis vaccine against Bordetella parapertussis infection. Clin Infect Dis. 1999;28:602-604. (Pubitemid 29242540)
18. Juretzko P, et al. Effectiveness of acellular pertussis vaccine assessed by hospital-based active surveillance in Germany. Clin Infect Dis. 2002; 35:162-167. (Pubitemid 34753901)
19. Zepp F, et al. Rationale for pertussis booster vaccination throughout life in Europe. Lancet Infect Dis. 2011;11:557-570.
20. Centers for Disease Control and Prevention (CDC). Updated recommendations for use of tetanus toxoid, reduced diphtheria toxoid and acellular pertussis (Tdap) vaccine from the Advisory Committee on Immunization Practices, 2010. Morb Mortal Wkly Rep. 2011;60:13-15.
21. Beytout J, et al. Safety of Tdap-IPV given 1 month after Td-IPV booster in healthy young adults: a placebo-controlled trial. Hum Vaccin. 2009;5:315-321.
22. Talbot EA, et al. The safety of immunizing with tetanus-diphtheria- acellular pertussis vaccine (Tdap) less than 2 years following previous tetanus vaccination: experience during a mass vaccination campaign of healthcare personnel during a respiratory illness outbreak. Vaccine. 2010;28: 8001-8007.